You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Maternal Serum Analyte Screening for Fetal Aneuploidy

CHASEN, STEPHEN T. MD*,†

Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0000000000000017
Noninvasive Screening for Fetal Aneuploidies: Eliminating Unwanted Surprises
Abstract

In the first and second trimesters, chemicals produced by the fetoplacental unit are measured to assess risks of fetal abnormalities. Consistent associations between levels of these proteins in such pregnancies enable these biomarkers to be used to calculate risk for Down syndrome and other chromosomal abnormalities in individual pregnancies. Special consideration may be required when assessing risk in multiple pregnancies and pregnancies achieved with infertility therapy.

Author Information

*NewYork-Presbyterian Hospital;

Weill Cornell Medical College, New York, New York

The author declares that there is nothing to disclose.

Correspondence: Stephen T. Chasen, MD, Weill Cornell Medical College, New York, NY. E-mail: stchasen@med.cornell.edu

© 2014 by Lippincott Williams & Wilkins.